Hemovent Receives Grant Totaling $810K from German Government

Hemovent GmbH, an Aachen, Germany-based venture backed medical device company, received a grant totaling $810k from the German Government.

The company intends to use the funds accelerate development of its novel and portable artificial lung technologies, designed for a wide range of applications from Extracorporeal CO2 Removal to ExtraCorporeal Life Support.

Led by Christof Lenz, co-founder and CEO, and Oliver Marseille, Ph.D., co-founder and CTO, Hemovent has developed small and self-contained fully portable artificial lungs for Extra Corporeal Membrane Oxygenation (ECMO) / ExtraCorporeal Life Support (ECLS) applications designed to support or replace heart and lung function in the event of cardiac and/or respiratory failure.

The company is backed by KfW Bank, MIG Verwaltungs, NRW.BANK.Venture Fonds, PB Beteiligung- und Vermoegensverwaltung, Seed Fond Aachen II, and WCTI Partners.



Join the discussion